The US FDA has granted 510(k) clearance for Australian company PolyNovo's (ASX:PNV) NovoSorb MTX which provides soft tissue regeneration for the management of complex wounds.
Major milestone for PolyNovo for FDA clearance of wound care innovation
September 19, 2022 Australian Biotech
Latest Video
New Stories
-
Novo Nordisk backs care for rural health professionals in southern NSW
August 19, 2026 - - Latest News -
Opportunity #3 - finally deliver on the repeated claims of patient-centricity
August 19, 2026 - - Latest News -
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - - Latest News -
Wesfarmers Health evolves its loyalty program with new Pulse Rewards
August 19, 2026 - -
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News

